Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SCG101 |
Synonyms | |
Therapy Description |
SCG101 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a T-cell receptor targeting HBsAg, which potentially induce cytotoxicity against tumor cells and enhance antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SCG101 | SCG-101|SCG 101 | SCG101 comprises CD4- and CD8-positive autologous T-lymphocytes engineered to express a T-cell receptor targeting HBsAg, which potentially induce cytotoxicity against tumor cells and enhance antitumor immune activity (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05417932 | Phase Ib/II | SCG101 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | Recruiting | USA | 2 |